Literature DB >> 17401441

Catecholamine outflow from mouse and rat brain slice preparations evoked by nicotinic acetylcholine receptor activation and electrical field stimulation.

P Scholze1, A Orr-Urtreger, J-P Changeux, J M McIntosh, S Huck.   

Abstract

BACKGROUND AND
PURPOSE: Mice with targeted deletions of neuronal nicotinic acetylcholine receptor (nAChR) subunit genes are valuable models to study nAChR function such as catecholamine outflow by presynaptic receptor activation. Contrary to the rat, our present knowledge on presynaptic nAChRs in mice primarily relies on observations made with synaptosomes. We have now used brain slices to investigate nicotine-induced catecholamine outflow in wild type (WT) and nAChR (beta2 and alpha5) knockout mice for a comparison with rat brain slice preparations. EXPERIMENTAL APPROACH: Brain slices from rat and mouse hippocampus, parieto-occipital neocortex, and corpus striatum were loaded with either [3H]-noradrenaline or [3H]-dopamine. We provoked catecholamine outflow by electrical field stimulation and nicotinic agonists. KEY
RESULTS: When set in relation to electrical field stimulation, nicotine-evoked catecholamine release was sizeable in the striatum but low in the neocortex of both rats and mice. [3H]-noradrenaline outflow was, on the other hand, substantial in the rat but low in the mouse hippocampus. About 10% (or less) of nicotine-induced catecholamine release persisted in the presence of tetrodotoxin in all our preparations. CONCLUSIONS AND IMPLICATIONS: Targeted deletion of the beta2 subunit gene essentially abolished the effect of nicotine, indicating that this subunit is an essential constituent of nAChRs that indirectly (via action potentials) induce catecholamine release from hippocampal and striatal slices in mice. The impact of nAChRs in catecholaminergic projection areas differs between species and has thus to be considered when extrapolating results from animal models to human conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401441      PMCID: PMC2013980          DOI: 10.1038/sj.bjp.0707236

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons.

Authors:  C Léna; A de Kerchove D'Exaerde; M Cordero-Erausquin; N Le Novère; M del Mar Arroyo-Jimenez; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Presynaptic nicotinic receptors modulating dopamine release in the rat striatum.

Authors:  S Wonnacott; S Kaiser; A Mogg; L Soliakov; I W Jones
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

3.  alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release.

Authors:  S Kaiser; S Wonnacott
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

4.  Selective deletion of the alpha5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse.

Authors:  Harald Fischer; Avi Orr-Urtreger; Lorna W Role; Sigismund Huck
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

5.  Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [3H]norepinephrine release from mouse hippocampal synaptosomes.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Mol Pharmacol       Date:  2006-05-30       Impact factor: 4.436

6.  Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum.

Authors:  F M Zhou; Y Liang; J A Dani
Journal:  Nat Neurosci       Date:  2001-12       Impact factor: 24.884

7.  Long-term potentiation of excitatory inputs to brain reward areas by nicotine.

Authors:  H D Mansvelder; D S McGehee
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

8.  Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype.

Authors:  M J Marks; J A Stitzel; S R Grady; M R Picciotto; J P Changeux; A C Collins
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal.

Authors:  Jacques Barik; Susan Wonnacott
Journal:  Mol Pharmacol       Date:  2005-11-03       Impact factor: 4.436

10.  Reinforcing effects of nicotine microinjections into the ventral tegmental area of mice: dependence on cholinergic nicotinic and dopaminergic D1 receptors.

Authors:  Vincent David; Morgane Besson; Jean-Pierre Changeux; Sylvie Granon; Pierre Cazala
Journal:  Neuropharmacology       Date:  2006-03-31       Impact factor: 5.250

View more
  16 in total

1.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

2.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

3.  Influence of prenatal nicotine exposure on development of the ventilatory response to hypoxia and hypercapnia in neonatal rats.

Authors:  Yu-Hsien Huang; Amanda Rose Brown; Seres J B Cross; Jesus Cruz; Amber Rice; Stuti Jaiswal; Ralph F Fregosi
Journal:  J Appl Physiol (1985)       Date:  2010-04-29

4.  α-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between α6ß4 and α6ß2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release.

Authors:  Layla Azam; Uwe Maskos; Jean-Pierre Changeux; Cheryl D Dowell; Sean Christensen; Mariella De Biasi; J Michael McIntosh
Journal:  FASEB J       Date:  2010-08-25       Impact factor: 5.191

5.  Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes.

Authors:  Reinhard David; Anna Ciuraszkiewicz; Xenia Simeone; Avi Orr-Urtreger; Roger L Papke; J M McIntosh; Sigismund Huck; Petra Scholze
Journal:  Eur J Neurosci       Date:  2010-03-03       Impact factor: 3.386

Review 6.  Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson's disease patients.

Authors:  Tomoyoshi Kondo
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

7.  Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex.

Authors:  Jun Zhu; Subbu Apparsundaram; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2008-12-16       Impact factor: 4.030

8.  GABAergic afferents activate both GABAA and GABAB receptors in mouse substantia nigra dopaminergic neurons in vivo.

Authors:  Elena Brazhnik; Fulva Shah; James M Tepper
Journal:  J Neurosci       Date:  2008-10-08       Impact factor: 6.167

Review 9.  Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

Authors:  J Zhu; M E A Reith
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

10.  N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.

Authors:  Linda P Dwoskin; Thomas E Wooters; Sangeetha P Sumithran; Kiran B Siripurapu; B Matthew Joyce; Paul R Lockman; Vamshi K Manda; Joshua T Ayers; Zhenfa Zhang; Agripina G Deaciuc; J Michael McIntosh; Peter A Crooks; Michael T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2008-05-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.